TrialPloS one2013

HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.

Allison Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.